Scholarlink

<p>A series of pyridoxine-based tris-ammonium compounds was synthesized. Primary <i>in vitro</i> screening of antibacterial activity of the synthesized compounds against six reference bacterial strains revealed four compounds whose activity is comparable with clinically used antiseptics (benzalkonium chloride, miramistin, and chlorhexidine). Further in-depth <i>in vitro</i> studies of cytotoxicity and antibacterial activity against clinical bacterial strains indicated that the most active lead-compound <b>1a</b> is safer than benzalkonium chloride, miramistin, and chlorhexidine and is more active against both Gram-positive and Gram-negative clinical strains.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis and antibacterial activity of pyridoxine-based tris-ammonium compounds

  • 期刊论文

  • 发表日期：

    2025年5月1日

查看全文
  • N. V. Shtyrlin,
  • E. S. Bulatova,
  • S. V. Sapozhnikov,
  • M. N. Agafonova,
  • E. D. Kobylinskaya,
  • E. A. Ocherednyuk,
  • V. A. Burilov,
  • Yu. G. Shtyrlin

摘要

A series of pyridoxine-based tris-ammonium compounds was synthesized. Primary in vitro screening of antibacterial activity of the synthesized compounds against six reference bacterial strains revealed four compounds whose activity is comparable with clinically used antiseptics (benzalkonium chloride, miramistin, and chlorhexidine). Further in-depth in vitro studies of cytotoxicity and antibacterial activity against clinical bacterial strains indicated that the most active lead-compound 1a is safer than benzalkonium chloride, miramistin, and chlorhexidine and is more active against both Gram-positive and Gram-negative clinical strains.